Catalyst
Slingshot members are tracking this event:
Initial Phase 1 clinical data for ALN-AAT in treating of AAT deficiency-associated liver disease to be presented at 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2016
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=991334
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aat Deficiency, Liver Disease, Phase 1, Clinical Data
